Astellas Retracts EMA Application for ACP
Astellas withdraws EMA application for ACP, pledges continued efforts for GA treatment in Europe.
Astellas Pharma recently decided to pull its European Medicines Agency (EMA) application for avacincaptad pegol (ACP), a drug designed to address geographic atrophy (GA) tied to age-related macular degeneration (AMD). Although clinical trials showed ACP could slow GA progression, discussions with EMA presented unexpected challenges, leading to this decision.
Despite the setback, Astellas reaffirmed its commitment to advancing ACP globally, including within Europe, where it will continue exploring other regulatory pathways. This reflects Astellas’ dedication to bringing innovative treatment options to patients who are grappling with the progressive vision loss that GA causes.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
More from Pharma News
All stories →
Pharming Group Gains FDA Approval for Leniolisib in Children Aged 4–11 with APDS
Lonza Builds Oregon Spray-Drying Facility To Expand SDD Capacity
Discussion